Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
(SANN) Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.
Related Questions
How does this partnership compare to Santhera's existing agreements in other regions and impact its competitive positioning against other DMD therapies?
How will the exclusive distribution agreement in India affect Santhera's revenue forecasts and earnings guidance?
What is the expected timeline for commercial launch, pricing strategy, and market size for Vamorolone in India?